Strand Therapeutics focuses on the development of programmable, long-acting mRNA therapeutics within the biotechnology sector. The company offers a platform for creating mRNA drugs that are designed to deliver precise, multi-functional, and potentially curative treatments by programming logic-based circuits into mRNA to control protein expression in targeted cells. Strand Therapeutics' products are primarily aimed at improving treatment options for cancer and other life-threatening diseases. It was founded in 2017 and is based in Boston, Massachusetts.

Baruch S. Blumberg Institute is a nonprofit organization that conducts translational research in the biotechnology sector, emphasizing virology and viral pathogenesis. The organization works on therapeutics for hepatitis B, liver cancer, and other viral diseases, as well as facilitating biotechnology through life science incubators. The Blumberg Institute also provides training and educational programs for the next generation of scientists. It was founded in 2003 and is based in Doylestown, Pennsylvania.

Atomic AI is a biotechnology company at the intersection of artificial intelligence and structural biology, focusing on ribonucleic acid (RNA) drug discovery. The company develops a proprietary platform that utilizes deep learning to discover small molecules and medicines that target RNA. It was founded in 2021 and is based in South San Francisco, California.

Versameb focuses on the discovery and development of ribonucleic acid (RNA) based drugs. The company provides solutions for modulating protein expression and influencing therapeutic targets using a molecular construct. Versameb's VERSagile technology platform supports the application of functional RNA in different disease contexts to expand the use of RNA therapeutics. It was founded in 2017 and is based in Basel, Switzerland.

Sidney Kimmel Cancer Center focuses on cancer awareness and education within the health sector. The center provides information and guidance on the signs, symptoms, and prevention of various types of cancer, with the goal of facilitating early detection. Its resources are designed to provide the public with knowledge about cancer-related health issues.

Sapreme Technologies is a preclinical-stage biotech company focused on developing RNA therapeutics for genetically driven diseases. The company's main offerings include endosomal escape technology that facilitates the delivery of large molecules such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to intracellular targets in various tissues, including the liver, muscle, heart, kidney, and brain. Sapreme's technology platform aims to improve receptor-targeted delivery and endosomal release of therapeutics in conditions like neuromuscular, renal, and cardiometabolic diseases. It was founded in 2016 and is based in Utrecht, Netherlands.